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Abstract
Radioactive iodine is utilized commonly for ablation of remnant thyroid tissue after
thyroidectomy and treatment of persistent disease and metastases in differentiated
thyroid cancer patients. As it involves ionizing radiation, it is important to ensure that
the patients receive optimum amount of radiation to destruct the target tissue while
keeping the radiation-related side effects to minimum. In clinical practice, standard
activity doses are preferred for thyroid cancer patients, assuming that biokinetics are
similar in all patients. Lately, many clinicians offered to individualise the radioactive
iodine  therapy  by  calculating  the  optimal  amount  of  radioactivity  using  patient
dosimetry.  Radiation  dosimetry  is  used  to  calculate  the  minimum  effective  and
maximum tolerated absorbed dose for a successful radioactive iodine therapy. This
approach  enables  to  administer  increased  amount  of  therapeutic  activity  while
minimizing the related side effects. This chapter presents some of the basic principles
of patient dosimetry and radioiodine biokinetics following radioactive iodine admin‐
istration in differentiated thyroid cancer patients.
Following radioactive iodine therapy, radiation protection measures are necessary to
protect the public from ionizing radiation after discharge of the patient from hospital.
Radiation exposure to patients, family members and caregivers and attempts to
decrease the exposure during therapy are also going to be discussed.
Keywords: radiation dosimetry, radiation exposure, dose rate, radioiodine therapy
1. Introduction
Radioactive iodine is an important component in treatment approach of differentiated thyroid
carcinoma patients. Following thyroidectomy, radioactive iodine is used for remnant tissue
ablation and to destroy residual tumor foci or metastatic disease. Traditionally a fixed dose of
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3700–7400 MBq (100–200 mCi) of radioiodine was recommended for treatment of residual disease
[1]. However, concerns related with ionizing radiation led to a significant decrease in the
administered dose recommended in the recent thyroid cancer management guidelines [2].
The optimum I-131 activity is controversial as the radioiodine biokinetics is different in each
patient. Therefore, radiation dosimetry is preferred especially in the subgroup of patients,
where selection of biologically effective dose is more crucial, such as patients with metastatic
disease, especially with lung metastases or with comorbidities such as chronic kidney disease,
as well as in pediatric and elderly population.
This chapter aims to present the basic principles of radiation dosimetry and common dosi‐
metric methods, as well as main dosimetric approaches for radiation dose selection for thyroid
carcinoma patients. Also, concerns about radiation exposure to patients, family members, and
caregivers and attempts to decrease the exposure during therapy are discussed.
2. Basic principles of radiation dosimetry
Radiation dosimetry is a general term implying the approach for (1) calculation of the mini‐
mum amount of radiation activity necessary for successful treatment of a patient (i.e., thera‐
peutic dose) for treatment planning using radionuclides or external beam radiotherapy, (2)
assessment of the radiation dose received by a specific organ or tissue of a patient to ensure
that radiation dose received by the patient would not exceed the tolerable limits of certain
organs or tissues, (3) determining the total radiation dose received by patients, health care
workers, or family members of patients to maintain radiation safety of individuals, (4)
measurement of the instantaneous and cumulative radiation dose in the environment where
ionizing radiation sources are used to ensure radiation safety of the workers and public, and
(5) calculation of the total amount of dose received by the fetus, in case the mother is exposed
to ionizing radiation during pregnancy. Radiation dosimetry for treatment planning of thyroid
cancer patients involves calculating the minimum amount of I-131 activity to be given to the
patient to ensure successful remnant thyroid tissue ablation or treatment of persistent disease
and metastases, as well as measuring the radiation dose received by critical or dose-limiting
organs to calculate the maximal safe dosage of I-131 that can be given to the patient.
There are two main approaches to determine the amount of I-131 to be given to the thyroid
cancer patients after thyroidectomy operation: empirical fixed amount approach, and dosi‐
metrically calculated amount approach. Empirical fixed amount approach is more widely
used, as it is a more simple and convenient method. However, it lacks the ability to accurately
incorporate the individual biological and physical features of patients, such as radioiodine
uptake, release, and residual functioning volume of thyroid tissue. On the other hand, current
individual dosimetric approaches are both demanding and inconvenient to calculate the exact
uptake and kinetics for each patient. However, it is especially crucial in the subgroup of thyroid
cancer patients, who require higher amount of radioiodine due to the presence of metastases
or relapsing disease.
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The tissue damage caused by ionizing radiation is dependent on many factors, such as the type
of radiation emitted, its amount and energy, its biokinetics in the body, including its uptake
and clearance in various organs, and the physical arrangement and location of organs emitting
radiation. Therefore, unlike external radiation sources, the doses received from internal
radiation sources used in nuclear medicine cannot be calculated exactly; rather several
formulas and assumptions are used to predict the radiation dose applied to the body.
2.1. Internal radiation dosimetry
The main aim of internal radiation dosimetry is to calculate the absorbed dose, which is defined
as the mean energy imparted to matter per unit mass by ionizing radiation. Absorbed dose (D)
is calculated using the following formula:
= (1)
where dε is the mean energy imparted by ionizing radiation and dm is the matter of mass.
In SI system, the unit for absorbed dose is joules per kilogram (J/kg) or ergs per gram (erg/g).
The special units for absorbed dose are gray (Gy) and rad:
41 J/kg=1Gy=100rad=10 erg/g
The term equivalent dose is derived from the absorbed dose to refer the different biological
effects of different types of ionizing radiation. It is calculated by multiplying the absorbed dose
by a radiation weighting factor (wR), which is dependent on the type and energy of radiation.
The formula for the equivalent dose (H) is therefore:
= ´ RH D w (2)
The unit for equivalent dose is the same as absorbed dose, as the radiation weighting factor
does not have a unit. However, special unit names are also defined for equivalent dose, which
are sievert (Sv) and rem. Radiation weighting factor is dependent on the type of radiation.
According to the International Commission on Radiological Protection (ICRP), alpha particles
have radiation weighting factor of 20, whereas the factor for beta minus, beta plus (positron),
gamma rays, and X-rays are 1:
1Sv 100 rem=
Absorbed dose for a certain organ or tissue can be calculated when the energy absorbed per
unit mass is identified. Several authors have established similar equations to calculate the
absorbed dose, which are known as the Marinelli method [3], Quimby method, Medical
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Internal Radiation Dose (MIRD) method [4], and International Commission on Radiological
Protection (ICRP) method. For the scope of our chapter, only MIRD method is going to be
explained in details, as it is the most commonly used method for radiation dosimetry calcu‐
lations in nuclear medicine.
A generic equation for the absorbed dose (D) in an organ or tissue has been established as [5,
6]:
f= å i i iikÃ n ED m (3)
where k is the proportionality constant, Ã is the cumulated activity (μCi-h or MBq-s), ni is the
number of particles with energy Ei emitted per nuclear transition, Ei is the energy per particle
(MeV), ϕi is the fraction of energy absorbed in the target, and m is the mass of the target region
(g or kg).
Source Target S-value
Bladder Bladder 1.2 × 10−3
Stomach Stomach 9.7 × 10−4
Kidney Kidney 1.5 × 10−3
Kidney Adrenal gland 3.2 × 10−5
Kidney Spleen 2.4 × 10−5
Thyroid gland Thyroid gland 2.2 × 10−2
Thyroid gland Whole body 9.5 × 10−6
Thyroid gland Lungs 2.9 × 10−6
Thyroid gland Bone marrow 2.4 × 10−6
Table 1. Some S-factors for I-131.
2.2. Medical internal radiation dose (MIRD) method
MIRD method was established by the Society of Nuclear Medicine to assist radiation dose
estimation to various organs using a simplified calculation method. Instead of using numerous
variables, MIRD method has shortened the absorbed dose equation by using the “S-factor” for
all the absorption parameters, which includes types and energy of radiation emitted, size and
shape of the target organ and other related organs, and energy fraction of each emission
absorbed in the target organ from radiation that originated in the source organ. S-factor is
ascertained for common radiopharmaceuticals, including I-131. S-factors for I-131 and Tc-99m
are given in Tables 1 and 2. Equation for the S-factor would be:
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=
∑ (4)
where k is the proportionality constant (=2.13), ni is the number of particles with energy Ei
emitted per nuclear transition, Ei is the energy per particle (MeV), Φi is the fraction of energy
absorbed in the target, and m is the mass of the target region (g or kg).
Source Target S-value
Liver Liver 4.6 × 10−7
Liver Kidneys 3.9 × 10−6
Liver Whole body 2.2 × 10−6
Liver Bone marrow 1.6 × 10−6
Liver Spleen 9.2 × 10−7
Spleen Spleen 3.3 × 10−4
Spleen Pancreas 1.9 × 10−5
Spleen Stomach 1.0 × 10−5
Spleen Whole body 2.2 × 10−6
Spleen Bone marrow 1.7 × 10−6
Spleen Liver 9.8 × 10−7
Bone marrow Bone marrow 3.1 × 10−5
Bone marrow Whole body 2.2 × 10−6
Bone marrow Liver 9.2 × 10−7
Table 2. Some S-factors for Tc-99m.
Finally, MIRD equation is as follows:
( )= ®åt s
s
D Ã S t s (5)
Ã = × (6)
where Ãs is the cumulated activity in the source organ, t is the target organ, s is the source
organ, A0 is the initial activity given, and τ is the residence time.
For the MIRD equation, various body phantoms, which represent human body and enable
accurate measurement of absorbed fractions, organ masses, and relationship of organs, were
established to determine the cumulated activity. Either external probes, such as thyroid uptake
device, or time-activity curves obtained from scintigraphic imaging are used to calculate the
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cumulative activity. Using MIRD equation, the calculation of radiation dose of patients after
radiopharmaceutical application is possible, but MIRD equation is not suitable for establish‐
ment of radiation dose received by radiation workers and family members.
Following the establishment of MIRD phantom, various other phantoms were introduced
representing human body more realistically, such as female and male phantoms, pregnant
female phantom [7], family phantoms including pediatric phantom series [8], and bone and
marrow phantom [9]. The data obtained using these phantoms are inserted in special software
programs dedicated for internal dose calculations, such as MIRDOSE [10] and OLINDA/EXM
1.0 [11].
The recent development in computer and anatomical imaging technologies led to the creation
of more realistic voxel phantoms, which include three-dimensional digital images of internal
organs and hybrid phantoms enabling a realistic and rapid modeling of human body (Figure 1)
[12, 13].
Figure 1. Adult male (A) and adult female (B) phantom by Segars [13]. There are also different age-specific phantoms
for dose evaluation in pediatric patients.
3. Dosimetric approaches for thyroid carcinoma
There are two main dosimetric approaches for administration of radioiodine for the treatment
of thyroid carcinoma: bone marrow-based approach, which aims to limit the radiation dose to
be within safe limits for bone marrow, and lesion-based approach, which aims to give at least
the minimum amount of radiation dose to destroy the lesions.
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3.1. Bone marrow-based dosimetric approach
Bone marrow depression is one of the most important complications of radioiodine therapy
as bone marrow is susceptible to ionizing radiation. Bone marrow-based dosimetry aims to
calculate the maximum amount of radiation that bone marrow can tolerate for radioiodine
treatment. This method was first developed by Benua et al. and it allows estimating the
radiation dose received by the hematopoietic system from each unit (GBq or mCi) of I-131
activity given to the patient [14]. The procedure involves an initial administration of a tracer
activity of I-131 to the patient, followed by serial blood sampling and whole-body activity
measurement for at least 4 days to follow the clearance of radioiodine from the body. Although
the name of this approach is bone marrow based, the calculations involve whole blood
compartment, not only the bone marrow. In the study by Benua et al., the group of patients
that received a whole blood dose of more than 200 cGy showed serious complications related
to ionizing radiation, whereas the group of patients that received less than 200 cGy to the blood
did not have serious side effects. Therefore, 2 Gy limit was proposed to be the safety limit for
bone marrow.
I-131 has both gamma (γ) and beta minus (β) radiation; so both radiation types are included
in radiation dose calculations. I-131 activity to be administered to the patient is calculated as
combined absorbed doses for gamma and beta radiation and is within safety limits for bone
marrow, which is accepted as 2 Gy:
( ) ( ) ( )
2
/ /= +administered β γ
 GyA MBq D Gy MBq D Gy MBq (7)
According to the original Benua protocol, a standard tracer I-131 activity was given to the
patient before the therapy and measurement of serial blood samples in a gamma counter is
performed for the detection of β-radiation dose (Dβ), whereas radiation dose for γ-radiation
(Dγ) is calculated either by serial measurement of the whole body of the patient using a gamma
probe or by measurement of the periodic urine collection.
After the introduction of the Benua protocol, several studies were performed with different
modifications to the original protocol, such as using gamma camera instead of gamma probe
[15], using geometric mean of the body activity counts instead of anterior measurement,
delaying the onset of whole body counting to 2 hours, and elimination of urine collection.
EANM Dosimetry Committee has also published a detailed guideline providing most recent
recommendations on how to perform blood- and bone marrow–based dosimetry in thyroid
cancer patients [16].
Further studies revealed that serious bone marrow toxicity is avoided in radiation doses of
less than 3 Gy; so 3 Gy is accepted today as bone marrow safety limit and it is used generally
for treatment of thyroid carcinoma patients with multiple metastases. Bone marrow dosimetry
is not recommended for patients with extended bone metastases, as blood-based absorbed
dose calculation could underestimate the absorbed dose to bone marrow [16]. Also, in the
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presence of multiple pulmonary micrometastasis, lung would be the critical organ instead of
bone marrow, therefore, bone marrow dosimetry would not be appropriate in those patients.
3.2. Lesion-based dosimetric approach
Bone marrow-based dosimetry aims to give the maximum safe amount of I-131, ignoring the
absorbed dose in the tumor, which may end up with giving a higher amount of radioiodine
than the actual therapeutic amount. Lesion-based dosimetric approach aims to calculate the
therapeutic amount of radioiodine that provides the minimum necessary radiation dose to the
residual thyroid tissue and metastatic foci. For lesion-based dosimetry, uptake and clearance
of I-131 from residual thyroid tissue and all metastatic foci are needed to be calculated.
Figure 2. Time-activity curve obtained from series of scintigraphic images of a thyroid cancer patient. Series of whole
body scintigraphy with empty bladder and rectum were acquired at different time points following tracer radioiodine
administration.
The lesion-based dosimetric approach was first described by Maxon et al. in 1983 in a study
with 76 thyroid carcinoma patients. Clinical response was detected in the group of patients
that received minimum 300 Gy radiation dose to residual thyroid tissue and 80 Gy to metastatic
foci, whereas less values were found to be inadequate for treatment [17].
The equation for assessment of lesion dose is as follows [18]:
(8)
where C0 is the initial concentration of I-131 in the lesion and T1/2 lesion is the effective half-life
of the lesion activity.
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To obtain the initial concentration of I-131 in the lesion, either serial whole body scintigraphic
imaging or radioiodine uptake test are performed after the administration of an initial tracer
I-131 activity. Using scintigraphic images, region of interest is drawn around the residual
thyroid tissue and all metastatic foci and time-activity curves are obtained to calculate the
initial activity and the effective half-life (Figure 2). Measurements were performed at the 2nd,
6th, 24th, 48th, 72nd, and 96th hours following radioiodine administration and additional
measurements are performed if the excretion is delayed. Also, the lesion mass is calculated
either using the gamma camera images or using radiological imaging tools, such as compu‐
terized tomography (CT) or ultrasonography (USG).
Selection of optimum administered dose is challenging in the presence of chronic renal failure,
as delayed excretion of radioiodine in these patients lead to increased radiation exposure of
the whole body including the critical dose limiting organs such as bone marrow. Dosimetry is
therefore recommended for these patients to refrain from radiation-related side effects and to
limit the exposure of the healthcare providers [19, 20].
3.3. Dosimetry using I-124
Traditionally, dosimetric methods for thyroid carcinoma involve use of low dose of I-131.
However, concerns about the stunning effect of I-131 limit its usage and lead to search for
alternative radionuclides, such as I-123 or I-124. I-123 is a cyclotron product with a half-life of
13 h. Being a pure gamma emitter, it is more favorable for diagnostic imaging but its supply
is limited. I-124 is also produced in a cyclotron, but it has a longer half-life of 4.18 days and it
is a positron emitter, which makes the isotope a promising tool for imaging of the residual
disease using PET/CT, for detection of patients who would benefit from radioiodine therapy
and for dosimetry of lesions especially for patients who require higher amount of radioiodine
[21].
I-124 PET-based dosimetry protocol involves serial PET/CT imaging starting 2–4 h after oral
administration of I-124 until 72–96 h. There are also simplified protocols proposed involving
imaging only at the 24th and 96th hours for lesion dosimetry [22]. Data obtained from I-124
PET/CT image can also be used to simplify the blood dose protocol, reducing the number of
blood sampling [23].
I-124 PET/CT was reported to provide a better assessment of lesion dosimetry in thyroid cancer
patients as it enables to determine the concentration of radionuclide in the lesion, providing
higher spatial resolution and imaging sensitivity than images acquired using gamma cameras
[24, 25]. Also, it allows estimating the lesion absorbed dose per administered I-131 activity for
each radioiodine positive tumor foci [24]. In a study investigating the relationship between the
absorbed radiation dose detected by I-124 PET and lesion response after I-131 administration,
similar response rates were found for thyroid remnant tissue compared to the historical data
of Maxon et al., who used planar I-131 scintigraphy to detect absorbed radiation dose [23]. It
was shown that I-124 PET/CT lesion dosimetry could be used as a prognostic tool to predict
lesion-based I-131 response [26]. Moreover, I-124 PET was found to be promising for detection
of radioiodine avidity of the remnant thyroid tissue and metastatic foci [27, 28]. However, high
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false negative rate of I-124 PET/CT was also reported in patients who had received rhTSH
stimulation [29].
4. Radiation safety
Increased usage of radiation in science, technology, and medicine led to a need for establish‐
ment of an international organization to provide recommendations on radiation protection.
International Commission on Radiological Protection (ICRP, former name “International X-
ray and Radium Protection Committee”) is an international, nongovernmental organization
that was founded in 1928 in Sweden to provide recommendations and guidance on radiation
protection.
4.1. Biological effects of radiation
Biological effects of radiation can be divided into two categories: deterministic effects and
stochastic effects.
Tissue/organ Effects Equivalent dose for
single exposure (Sv)
Equivalent dose rate for
prolonged exposure (Sv/year)
Testis Temporary infertility 0.15 0.4
Permanent infertility >3.5 2.0
Ovaries Permanent infertility >2.5 >0.2
Lens of
the eye
Detectable opacities >0.5 >0.1
Cataract >2.0 >0.15
Bone marrow Impairment of blood
cell production
>0.5 >0.4
Table 3. Threshold for deterministic for different tissues and organs by ICRP [30].
Deterministic effects can be seen in medium to high radiation doses. The effects related with
radiation are seen only above a certain threshold, when there is loss of tissue function and the
damage will increase with the absorbed dose. Bone marrow, testis, and lens of the eye are the
most sensitive tissues for radiation; therefore, deterministic effects such as pancytopenia,
infertility, and cataract are first seen in those tissues. Although skin is not one of the most
sensitive organs for radiation, erythema is another common deterministic effect, which occurs
due to accidental skin contamination. Doses of radionuclides used for nuclear medicine
imaging procedures are below the threshold for deterministic effects. During radionuclide
therapy, including I-131 therapy for thyroid cancer, doses are selected that exceed the deter‐
ministic threshold only for the thyroid tissue, preserving the other tissues. ICRP has published
recommendations including the thresholds for deterministic effects of different tissues and
organs (Table 3) [30].
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Stochastic effects can be seen in low level of exposure, there is not a certain threshold for the
effects and the severity is not dependent on the absorbed dose. The name stochastic is given
to refer that the effects can be seen by chance and the proportion of the population that are
effected can be predicted statistically but the exact persons that will be affected cannot be
foreseen. Stochastic effects occur when radiation does not kill the cell but modifies its DNA.
Radiation-related cancers and hereditary disorders are examples for stochastic effects of
radiation.
4.2. Practical dosimetry
Despite many advantages of radiation dosimetry, it is difficult to be performed for all thyroid
carcinoma patients undergoing radioiodine therapy. Some information, on the other hand,
obtained from dosimetry principles can guide clinicians in treatment planning of patients.
Retention of radioiodine can be easily determined using a standard uptake probe and if high
radioiodine retention is detected, prescribed radioiodine dose could be decreased to ensure
safety [31]. On the contrary, if radioiodine retention is low, then prescribed dose of I-131 could
be increased to optimize the efficacy. Bone marrow is the dose-limiting organ for radioiodine
therapy, as the bone marrow depression is one of the most important complications of the
therapy. Radiation to blood and to bone marrow is correlated with body retention. Also,
increased serum thyroxine concentration in the blood in the absence of thyroid hormone
medication can be used as an indicator of increased blood radiation and reduction of prescribed
activity could be taken into consideration. Thyroid carcinomas, which are at least 1 cm in
diameter but are not visible on scintigraphic image, usually cannot be eliminated with a usual
therapeutic I-131 dose of 3700–7400 MBq (100–200 mCi); therefore, either dose increase or
dosimetric approaches should be considered for those patients [31]. Presence of radiation-
related side effects after the first radioiodine therapy, such as bone marrow toxicity, sialade‐
nitis, and lacrimal gland dysfunction, should be assessed prior further therapy planning to
avoid cumulative radiation toxicity.
4.3. Radiation-related risks in thyroid cancer patients
The risk of radioiodine-related secondary cancer in thyroid cancer patients is controversial.
There are several long-term follow-up studies investigating the secondary malignancies in
thyroid cancer patients and only a very low associated risk of malignancy could be found.
Therefore, recent thyroid cancer management guidelines do not recommend any specific
screening after radioiodine administration in thyroid cancer patients [2]. The risk of secondary
cancers is dose related and generally seen in patients who receive cumulative I-131 activity of
more than 22,200 MBq (600 mCi) and there is no direct evidence of increased risk in patients
who have received 1110–3700 MBq (30–100 mCi) radioiodine in a single session [32]. In a meta-
analysis including 16,502 patients from two distinct multicenter studies, overall risk of
secondary cancer was shown to be increased by 1.2 (95% CI: 1.04–1.36; p < 0.01) [33]. The most
significant risk increase was reported to be in leukemias, with a relative risk of 2.5 (95% CI:
1.13–5.53; p < 0.024) [33]. Other cancers reported to have increased risk are bone and soft tissue
cancers, breast cancer, colorectal cancer, salivary gland tumors, and kidney cancer [32, 34, 35].
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There are also several other studies that show increased risk of secondary malignancies in
thyroid cancer patients, that is not associated with radioiodine administration [36, 37].
4.4. Radiation safety precautions for family members and public
Three of basic elements of radiation safety are distance, shielding, and time. Distance is the
most important and simple way to ensure radiation safety. For point sources, the intensity of
radiation is inversely related with the square of distance (inverse square law). For nonpoint
sources, such as the patients, this law is not as accurate as in point sources, but still the exposure
decreases as the distance in between increases. Shielding is another important parameter to
ensure radiation safety. During radioiodine therapy, protection against beta and gamma
radiation of I-131 is necessary. Beta radiation can be absorbed in a few centimeters of wood
and they cannot penetrate out of patient body. Gamma rays are absorbed by atoms with heavy
nuclei, such as lead. Reducing the exposure time reduces the cumulative dose proportionally.
So the shorter time patients spend with their family, the smaller the radiation dose the family
members receive.
ICRP and International Atomic Energy Agency (IAEA) recommend a dose limit of 1 mSv/year
to the general public and 5 mSv/year to family members and caregivers of patients who have
received radionuclide therapy (Table 4) [30, 38]. According to the European Atomic Energy
Community (EURATOM), patients are allowed to be discharged after a radiation dose rate
limit of 20 μSv/h at 1 m is achieved. After discharge, patients are advised to take further
precautions at home.
Organ or tissue Radiation worker (mSv/year) Public (mSv/year)
Whole body 20 1
Gonads 50 5
Bone marrow 50 5
Bone 500 50
Skin 500 50
Thyroid gland 500 50
Extremities 500 75
Table 4. Dose limits to radiation workers and public recommended by ICRP.
Patients undergoing radioiodine therapy for thyroid cancer treatment and ablation are
hospitalized in radionuclide therapy units to ensure proper shielding and waste control.
Special precautions are taken in design of the patient rooms: The walls are lead lined to limit
the gamma ray exposure of the health care workers and other patients. Also, lead lined tanks
are used to store the waste of patients for decay to limit the release of I-131 to public sewage
system. After discharge, patients are advised to maximize their distance from pregnant women
and children, sleep in separate beds, to avoid spending extended time in public places, and to
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limit travel for some time depending on the amount of radioiodine given [39, 40]. Also, several
attempts are being discussed to decrease the radiation-related side effects of the patient, such
as increased amount of daily water intake, frequent urination to decrease the absorbed dose
to kidneys and bladder, and chewing-gum stimulation to decrease the absorbed dose to
salivary glands [41]. Pregnancy is contra-indicated for radioiodine administration and
according to ICRP female patients are advised to refrain from pregnancy for at least 4 months
following radioiodine administration. Also, breast-feeding is not allowed after radioiodine
administration.
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